Fluorescence activation mechanism and imaging of drug permeation with new sensors for smoking-cessation ligands

Nicotinic partial agonists provide an accepted aid for smoking cessation and thus contribute to decreasing tobacco-related disease. Improved drugs constitute a continued area of study. However, there remains no reductionist method to examine the cellular and subcellular pharmacokinetic properties of these compounds in living cells. Here, we developed new intensity-based drug sensing fluorescent reporters (“iDrugSnFRs”) for the nicotinic partial agonists dianicline, cytisine, and two cytisine derivatives – 10-fluorocytisine and 9-bromo-10-ethylcytisine. We report the first atomic-scale structures of liganded periplasmic binding protein-based biosensors, accelerating development of iDrugSnFRs and also explaining the activation mechanism. The nicotinic iDrugSnFRs detect their drug partners in solution, as well as at the plasma membrane (PM) and in the endoplasmic reticulum (ER) of cell lines and mouse hippocampal neurons. At the PM, the speed of solution changes limits the growth and decay rates of the fluorescence response in almost all cases. In contrast, we found that rates of membrane crossing differ among these nicotinic drugs by > 30 fold. The new nicotinic iDrugSnFRs provide insight into the real-time pharmacokinetic properties of nicotinic agonists and provide a methodology whereby iDrugSnFRs can inform both pharmaceutical neuroscience and addiction neuroscience.

[1]  R. Campbell,et al.  Structure- and mechanism-guided design of single fluorescent protein-based biosensors , 2021, Nature Chemical Biology.

[2]  Elizabeth K. Unger,et al.  Directed Evolution of a Selective and Sensitive Serotonin Sensor via Machine Learning , 2020, Cell.

[3]  Amol V. Shivange,et al.  A fast genetically encoded fluorescent sensor for faithful in vivo acetylcholine detection in mice, fish, worms and flies , 2020, bioRxiv.

[4]  C. Fan.  Structure, Function, and Application of Bacterial ABC Transporters , 2020 .

[5]  Charlene H. Kim,et al.  Biosensors Show the Pharmacokinetics of S-Ketamine in the Endoplasmic Reticulum , 2019, Front. Cell. Neurosci..

[6]  H. Lester,et al.  Probing Binding Interactions of Cytisine Derivatives to the α4β2 Nicotinic Acetylcholine Receptor. , 2019, Journal of the American Chemical Society.

[7]  Sripriya Ravindra Kumar,et al.  Publisher Correction: Systemic AAV vectors for widespread and targeted gene delivery in rodents , 2019, Nature Protocols.

[8]  T. Cordes,et al.  Single-Molecule Observation of Ligand Binding and Conformational Changes in FeuA , 2019, bioRxiv.

[9]  M. Michaelides,et al.  Ultrapotent chemogenetics for research and potential clinical applications , 2019, Science.

[10]  Charlene H. Kim,et al.  Determining the pharmacokinetics of nicotinic drugs in the endoplasmic reticulum using biosensors , 2019, The Journal of general physiology.

[11]  J. Sheridan,et al.  Plasma concentrations of cytisine, a commercially available plant-based alkaloid, in healthy adult smokers taking recommended doses for smoking cessation , 2018, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  D. Rees,et al.  Noncanonical role for the binding protein in substrate uptake by the MetNI methionine ATP Binding Cassette (ABC) transporter , 2018, Proceedings of the National Academy of Sciences.

[13]  R. Hurst,et al.  The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data , 2018, Psychopharmacology.

[14]  R. Hurst,et al.  The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data , 2018, Psychopharmacology.

[15]  R. Sessions,et al.  Unlocking Nicotinic Selectivity via Direct C‒H Functionalization of (−)-Cytisine , 2018, Chem.

[16]  David Fitzpatrick,et al.  Stability, affinity and chromatic variants of the glutamate sensor iGluSnFR , 2018, Nature Methods.

[17]  W. N. Green,et al.  Selective and regulated trapping of nicotinic receptor weak base ligands and relevance to smoking cessation , 2017, eLife.

[18]  H. Lester,et al.  Secondary Ammonium Agonists Make Dual Cation-π Interactions in α4β2 Nicotinic Receptors , 2017, eNeuro.

[19]  Mikhail Drobizhev,et al.  Deciphering the molecular mechanism responsible for GCaMP6m's Ca2+-dependent change in fluorescence , 2017, PloS one.

[20]  C. L. Morales-Pérez,et al.  X-ray structure of the human alpha 4 beta 2 nicotinic receptor. , 2016 .

[21]  C. L. Morales-Pérez,et al.  X-ray structure of the human α4β2 nicotinic receptor , 2016, Nature.

[22]  T. Pieńko,et al.  Cytisine basicity, solvation, logP, and logD theoretical determination as tool for bioavailability prediction. , 2016, Journal of molecular graphics & modelling.

[23]  H. Lester,et al.  Inside-out neuropharmacology of nicotinic drugs , 2015, Neuropharmacology.

[24]  N. Vassilev,et al.  Cytisine as a Scaffold for ortho-Diphenylphosphinobenzenecarboxamide Ligands for Pd-Catalyzed Asymmetric Allylic Alkylation. , 2015 .

[25]  N. Vassilev,et al.  Cytisine as a scaffold for ortho-diphenylphosphinobenzenecarboxamide ligands for Pd-catalyzed asymmetric allylic alkylation , 2015 .

[26]  B. Poolman,et al.  Conformational dynamics in substrate-binding domains influences transport in the ABC importer GlnPQ , 2014, Nature Structural &Molecular Biology.

[27]  Manfred T Reetz,et al.  Reducing codon redundancy and screening effort of combinatorial protein libraries created by saturation mutagenesis. , 2013, ACS synthetic biology.

[28]  Mark T. Harnett,et al.  An optimized fluorescent probe for visualizing glutamate neurotransmission , 2013, Nature Methods.

[29]  H. Waterbeemd,et al.  Pharmacokinetics and Metabolism in Drug Design: SMITH:PHARMACOKINETICS 3E O-BK , 2012 .

[30]  A. Kruse,et al.  Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.

[31]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[32]  H. Lester,et al.  Nicotine up-regulates α4β2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning , 2011, The Journal of general physiology.

[33]  L. Castellano,et al.  Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. , 2011, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[34]  D. Bertrand,et al.  Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence , 2010, British journal of pharmacology.

[35]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[36]  D. Svinarov,et al.  Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits , 2010, Interdisciplinary toxicology.

[37]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[38]  K. Wilson,et al.  Efficacy of pharmacotherapies for short-term smoking abstinance: A systematic review and meta-analysis , 2009, Harm reduction journal.

[39]  Jingdong Tian,et al.  Circular Polymerase Extension Cloning of Complex Gene Libraries and Pathways , 2009, PloS one.

[40]  Daniel Yohannes,et al.  Diversity-oriented synthesis of a cytisine-inspired pyridone library leading to the discovery of novel inhibitors of Bcl-2. , 2009, Bioorganic & medicinal chemistry letters.

[41]  Henry A. Lester,et al.  Nicotine Binding to Brain Receptors Requires a Strong Cation-π Interaction , 2009, Nature.

[42]  Yuichiro Hori,et al.  [Crystal structure of the Aequorea victoria green fluorescent protein]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[43]  A. Kozikowski,et al.  Chemical Medicine: Novel 10‐Substituted Cytisine Derivatives with Increased Selectivity for α4β2 Nicotinic Acetylcholine Receptors , 2007 .

[44]  A. Kozikowski,et al.  Chemical medicine: novel 10-substituted cytisine derivatives with increased selectivity for alpha4beta2 nicotinic acetylcholine receptors. , 2007, ChemMedChem.

[45]  J. Rouden,et al.  Regio- and diastereoselective functionalization of (−)-cytisine , 2006 .

[46]  A. Kozikowski,et al.  Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. , 2006, Journal of medicinal chemistry.

[47]  K. Fagerström,et al.  Neuropharmacology and potential efficacy of new treatments for tobacco dependence , 2006, Expert opinion on investigational drugs.

[48]  A. Kuryatov,et al.  Nicotine Acts as a Pharmacological Chaperone to Up-Regulate Human α4β2 Acetylcholine Receptors , 2005, Molecular Pharmacology.

[49]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[50]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[51]  B. Willemse.  Smoking cessation in chronic obstructive pulmonary disease , 2005 .

[52]  J. Lindstrom,et al.  Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors. , 2005, Molecular pharmacology.

[53]  F. Tingley,et al.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. , 2005, Journal of medicinal chemistry.

[54]  N. Benowitz,et al.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.

[55]  T. Sixma,et al.  Nicotine and Carbamylcholine Binding to Nicotinic Acetylcholine Receptors as Studied in AChBP Crystal Structures , 2004, Neuron.

[56]  Kay Diederichs,et al.  Cation-π Interactions as Determinants for Binding of the Compatible Solutes Glycine Betaine and Proline Betaine by the Periplasmic Ligand-binding Protein ProX from Escherichia coli* , 2004, Journal of Biological Chemistry.

[57]  J. L. Houezec,et al.  Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. , 2003 .

[58]  G. Perrault,et al.  SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[59]  J. le Houezec.  Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[60]  G. Perrault,et al.  SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. , 2003, The Journal of pharmacology and experimental therapeutics.

[61]  J. Rouden,et al.  Regio- and diastereoselective functionalization of (−)-cytisine: an unusual N–C acyl migration , 2002 .

[62]  Martin K. Bayliss,et al.  Pharmacokinetics and Metabolism in Drug Design , 2002 .

[63]  P. Imming,et al.  Syntheses and evaluation of halogenated cytisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands. , 2001, European journal of medicinal chemistry.

[64]  D. Dougherty,et al.  A computational study of nicotine conformations in the gas phase and in water. , 2000, The Journal of organic chemistry.

[65]  R. Tsien,et al.  green fluorescent protein , 2020, Catalysis from A to Z.

[66]  S J Remington,et al.  Structural basis for dual excitation and photoisomerization of the Aequorea victoria green fluorescent protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Lipoldová,et al.  Resistance to Leishmania major in Mice , 1996, Science.

[68]  E. Levin,et al.  Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone , 1994, Clinical pharmacology and therapeutics.

[69]  D. Lancet,et al.  Kinetic evidence for hapten-induced conformational transition in immunoglobin MOPC 460. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Ballard,et al.  Overview of the CCP 4 suite and current developments , 2022 .

[71]  G. Edelman,et al.  Kinetic evidence for hapten-induced conformational transition in immunoglobulin MOPC 460 , 2022 .